BRPI0512281A - análise dimensional de conjugados de sacarìdeo com gpc & sec-mals - Google Patents

análise dimensional de conjugados de sacarìdeo com gpc & sec-mals

Info

Publication number
BRPI0512281A
BRPI0512281A BRPI0512281-3A BRPI0512281A BRPI0512281A BR PI0512281 A BRPI0512281 A BR PI0512281A BR PI0512281 A BRPI0512281 A BR PI0512281A BR PI0512281 A BRPI0512281 A BR PI0512281A
Authority
BR
Brazil
Prior art keywords
mals
gpc
sec
sample
dimensional analysis
Prior art date
Application number
BRPI0512281-3A
Other languages
English (en)
Inventor
Giorgio Capannoli
Valeria Carinci
Sandro D Ascenzi
Claudia Magagnoli
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BRPI0512281A publication Critical patent/BRPI0512281A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

ANáLISE DIMENSIONAL DE CONJUGADOS DE SACARìDEO COM GPC & SEC-MALS. Trata-se de GPC (cromatografia de permeação com gel) e cromatografia de exclusão por dimensionamento com detecção através de fotometria de dispersão de luz por múltiplos ângulos (SEC-MALS), que podem ser usados para medir, com precisão, o tamanho molecular e massa molar, respectivamente, dos conjugados de sacarídeo. A invenção proporciona (a) um processo para medir o tamanho molecular de um antígeno de sacarídeo conjugado dentro de uma amostra, que compreende uma etapa de analisar a amostra através de GPC, e (b) um processo para medir a massa molar de um antígeno de sacarídeo conjugado dentro de uma amostra, que compreende uma etapa de analisar a amostra através de SEC-MALS.
BRPI0512281-3A 2004-06-21 2005-06-21 análise dimensional de conjugados de sacarìdeo com gpc & sec-mals BRPI0512281A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413868.1A GB0413868D0 (en) 2004-06-21 2004-06-21 Dimensional anlaysis of saccharide conjugates
PCT/IB2005/002532 WO2006000920A2 (en) 2004-06-21 2005-06-21 Dimensional analysis of saccharide conjugates with gpc & sec-mals

Publications (1)

Publication Number Publication Date
BRPI0512281A true BRPI0512281A (pt) 2008-02-26

Family

ID=32750313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512281-3A BRPI0512281A (pt) 2004-06-21 2005-06-21 análise dimensional de conjugados de sacarìdeo com gpc & sec-mals

Country Status (13)

Country Link
US (2) US8163296B2 (pt)
EP (2) EP1778291B1 (pt)
JP (5) JP2008503716A (pt)
CN (1) CN1976725B (pt)
AU (1) AU2005256961B2 (pt)
BR (1) BRPI0512281A (pt)
CA (1) CA2571565C (pt)
ES (2) ES2443465T3 (pt)
GB (1) GB0413868D0 (pt)
MX (2) MXPA06015188A (pt)
NZ (1) NZ552449A (pt)
RU (1) RU2422156C2 (pt)
WO (1) WO2006000920A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
TW201009337A (en) 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
WO2010141426A1 (en) 2009-06-01 2010-12-09 Waters Technologies Corporation Hybrid material for chromatographic separations
US8195405B2 (en) * 2009-06-30 2012-06-05 Wyatt Technology Corporation Method for characterizing reversible association of macromolecules at high concentration
PL2493498T3 (pl) * 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
EP4023330A1 (en) * 2009-12-15 2022-07-06 Waters Technologies Corporation Device and methods for performing size exclusion chromatography
CN102905728B (zh) * 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
US12623205B2 (en) 2010-07-26 2026-05-12 Waters Technologies Corporation Superficially porous materials comprising a substantially nonporous hybrid core having narrow particle size distribution
JP6199184B2 (ja) 2010-07-26 2017-09-20 ウオーターズ・テクノロジーズ・コーポレイシヨン 粒度分布の狭い実質的に非多孔質のコアを含む表面多孔質材料、その製造方法及びクロマトグラフィー分離用としてのその使用
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN109459523B (zh) * 2017-09-06 2022-11-08 上海绿谷制药有限公司 一种测定酸性糖可溶性盐重均分子量和含量的方法
CN109459504B (zh) * 2017-09-06 2022-05-27 绿谷(上海)医药科技有限公司 一种测定聚古罗糖醛酸硫酸酯盐重均分子量和含量的方法
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7409055B2 (ja) * 2019-12-05 2024-01-09 株式会社島津製作所 検出器の出力を補正する方法、および多角度光散乱検出器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
PT2332581E (pt) * 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
US20030035806A1 (en) * 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates

Also Published As

Publication number Publication date
WO2006000920A3 (en) 2006-03-30
CA2571565A1 (en) 2006-01-05
EP1778291A2 (en) 2007-05-02
GB0413868D0 (en) 2004-07-21
ES2443465T3 (es) 2014-02-19
JP6661568B2 (ja) 2020-03-11
WO2006000920A2 (en) 2006-01-05
JP2014111654A (ja) 2014-06-19
MXPA06015188A (es) 2007-03-27
CA2571565C (en) 2014-08-12
RU2422156C2 (ru) 2011-06-27
AU2005256961B2 (en) 2011-06-23
US8163296B2 (en) 2012-04-24
MX344621B (es) 2017-01-03
AU2005256961A1 (en) 2006-01-05
JP2008503716A (ja) 2008-02-07
JP6218327B2 (ja) 2017-10-25
US20120207781A1 (en) 2012-08-16
JP2011246490A (ja) 2011-12-08
CN1976725B (zh) 2012-08-29
ES2688796T3 (es) 2018-11-07
JP2015180707A (ja) 2015-10-15
NZ552449A (en) 2010-05-28
EP1778291B1 (en) 2013-10-30
US20080248059A1 (en) 2008-10-09
EP2374473B1 (en) 2018-07-18
CN1976725A (zh) 2007-06-06
EP2374473A1 (en) 2011-10-12
RU2007102016A (ru) 2008-07-27
JP2017134084A (ja) 2017-08-03

Similar Documents

Publication Publication Date Title
MX344621B (es) Analisis dimensional de conjugados sacaridos con cromatografia de permeacion en gel y cromatografia de exclusion de tamaño con deteccion mediante fotometria de dispersion de luz de angulos multiples.
WO2007090147A3 (en) Method and apparatus for measurement of optical properties in tissue
DE602004028445D1 (de) Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
SE0800724L (sv) Blodviskositetsanalys
ATE532051T1 (de) Differenzielle reflexionsspektroskopieverfahren zur erkennung von sprengstoffen
EP1845363A3 (en) Sample analyzer
AR054474A1 (es) Formulacion de anticuerpos estables
AR031557A1 (es) Sonda optica y metodos para analisis espectral.
EP1975623A3 (en) Sample analyzer
EP1359417A3 (en) Devices and methods for analyte concentration determination
BRPI0008719B8 (pt) Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
BRPI0606807A2 (pt) dispositivo para analisar partìculas em uma amostra e método para analisar partìculas em uma amostra que contém as referidas partìculas
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
BR112018016018A2 (pt) sensor e dispositivo para aplicações de imagem e de deteção do tempo de vida útil
CY1114655T1 (el) Μεθοδος για την ποσοτικη αναλυση διαλυματων και διασπορων μεσω σχεδον υπερυθρης φασματοσκοπιας
ATE551055T1 (de) Nachweis von succinylaceton
NO20023811L (no) Sammensetninger og fremgangsmåter for overflatepreging
BRPI0909825B8 (pt) método e sistemas para detecção não-invasiva de glicose sanguíneo utilizando dados espectrais de um ou mais componentes que não a glicose
WO2005040759A3 (en) Apparatus and methods for detecting target analyte
NO20080166L (no) Spektrometeranordning for maling av forskjovede spektrale distribusjoner
WO2007067819A3 (en) Optical molecular detection
DE502004011786D1 (de) Vorrichtung und verfahren zur messung optischer eigenschaften eines objekts
BR112022020549A2 (pt) Método aperfeiçoado para quantificação de polissacarídeos
ATE528635T1 (de) Partikelkonzentrations-messvorrichtung und messverfahren

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/095 (2006.01), A61K 47/64 (2017.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT)

B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT)

Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2547 DE 29/10/2019 POR NAO TER SIDO DISPONIBILIZADO O PARECER.

B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]